Chronic Kidney Disease
Business Services · 11-50 Employees
View Company Info for Free
Overview
Website
www.ckdqld.orgRevenue
<$5 MillionIndustry
About Chronic Kidney Disease
Chronic Kidney Disease Org Chart
Is Chronic Kidney Disease your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Chronic Kidney Disease launches new products
Earning: See what the market has to say on Chronic Kidney Disease recently announced quarterly report
Click to see if Chronic Kidney Disease had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Chronic Kidney Disease has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Chronic Kidney Disease
Check out if Chronic Kidney Disease is spiking on competitors!
Funding: Get notified immidiatlly once Chronic Kidney Disease has new funding data
Chronic Kidney Disease, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Chronic Kidney Disease
Compare insights from companies similar to Chronic Kidney Disease, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Chronic Kidney Disease is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Chronic Kidney Disease is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Chronic Kidney Disease.
Chronic Kidney Disease Tech Stack
A closer look at the technologies used by Chronic Kidney Disease
Chronic Kidney Disease News & Media
Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With Chronic Kidney Disease
BERLIN--(BUSINESS WIRE)--Bayer announced today the start of ALPINE-1 study, a Phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, in patients with chronic kidney disease (CKD). The results of this study have the potential to provide evidence of the sGC activator as a viable treatment option for cardiovascular diseases. CKD is a progressive condition that affects more than 10% of the global population, totaling approximately 850 million individuAstellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
TOKYO, Nov. 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO®...Bayer’s FIDELIO-DKD Phase III Study Demonstrated Investigational Drug Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of chronic kidney disease (CKD) in patients with CKD and type 2 diabetes (T2D) compared to placebo. In the study, finerenone significantly reduced the risk of the composite primary endpoint of time to kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) greater than or equal tNew Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined
TOKYO, Oct. 19, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, PhD, "Astellas") today announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week...
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Chronic Kidney Disease
CKD.QLD is an initiative of the University of Queenslands Centre for Chronic Disease, in partnership with Queensland Health and Queensland University of Technology. CKD.QLD is a collaborative, multidisciplinary practice program, established in July 2009. CKD.QLD encompasses a CKD Registry, database and practice network, with the purpose of improvin... Read More